No cookies!

Cookies disabled. It’s not us, it’s your browser. Your Web browser must have cookies enabled for you to use all of the site’s functions.


At week 12, a larger reduction in ICSS favoring Xiidra vs vehicle was observed in 3 of the 4
clinical studies1

Four randomized, double-masked, 12-week studies evaluated the efficacy and safety of Xiidra vs vehicle in subjects with Dry Eye Disease (N=2133). Each of the 4 studies assessed the effect of Xiidra vs vehicle on both the signs and symptoms of Dry Eye at baseline and weeks 2, 6, and 12. Assessment of signs was based on change from baseline in Inferior Corneal Staining Score (ICSS). ICSS was measured on a scale of 0 to 4 in increments of 0.5. The average baseline ICSS was approximately 1.8 in Studies 1 and 2 and 2.4 in Studies 3 and 4.1

Mean change (SD) from baseline and Treatment Difference (Xiidra – Vehicle) in ICSS1

Mean change (SD) from baseline and Treatment Difference (Xiidra – Vehicle) in ICSS1

Mean change (SD) from baseline and Treatment Difference (Xiidra – Vehicle) in ICSS1

Mean change (SD) from baseline and Treatment Difference (Xiidra – Vehicle) in ICSS1

*Based on ANCOVA model adjusted for baseline value in Study 1, and ANCOVA model adjusted for baseline value and randomization stratification factors in Studies 2 to 4. All randomized and treated patients were included in the analysis and missing data were imputed using last-available data. In Study 2, one vehicle-treated subject who did not have a study eye designated was excluded from analysis.

CI = Confidence Interval

Want to learn more about Xiidra and Shire?

Tell us your e-mail address:

*First Name *Last Name

*All fields are required.

For US residents only.
All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our privacy policy statement. We encourage you to read our privacy policy statement by clicking on this link: Review Shire privacy policy statement.

This consent will be in effect until such time as you opt out of the program.

NIICE Thanks for registering. We’re really looking forward to sending you updates.


Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.


  1. Xiidra [Prescribing Information]. Lexington, MA: Shire US.